title: Sustained phospholipase D activation in response to angiotensin II but not carbachol in bovine adrenal glomerulosa cells.
abstract: We have demonstrated previously that in bovine adrenal glomerulosa cells, phospholipase D (PLD) activity can indirectly result in the generation of sn-1,2-diacylglycerol (DAG) through its production of phosphatidic acid (PA) and the subsequent action of PA phosphohydrolase. Furthermore, the PLD-generated DAG can trigger aldosterone secretion. Therefore, we characterized PLD activation by two agonists, angiotensin II (Ang II) and carbachol, to determine if the activity of the enzyme might underlie sustained aldosterone secretion. We determined that Ang II-induced PLD activation occurred via the angiotensin-1 receptor (AT1), and that a specific AT1 antagonist, losartan, inhibited this activation, whereas the same concentration of the AT2-specific antagonist, PD 123319, had no effect. Ang II activated PLD with a dose dependence similar to that observed for aldosterone secretion, with slight increases in activity induced by 0.1 nM Ang II and maximal activation at 10 nM. We also found that Ang II induced a sustained activation of PLD, but that the effect of carbachol, a stable analogue of acetylcholine, was transient; PLD activity increased within 5 min of exposure to carbachol but then ceased by 15 min. Higher carbachol concentrations were also unable to sustain PLD activation. These results suggest that the Ang II-elicited activation of PLD is associated with a sustained increase in aldosterone secretion from glomerulosa cells and further provide the first evidence, to our knowledge, of differences in the kinetics of PLD activation in response to two physiologically relevant agonists. Finally, we speculate that this disparity correlates with different functional responses induced by the two agents.
authors.affiliation: Department of Medicine, Institute of Molecular Medicine and Genetics, Medical College of Georgia, 1120 15th Street, Augusta, GA 30912, USA.
authors.forename: E
authors.initials: E
authors.lastname: Jung
authors.forename: S
authors.initials: S
authors.lastname: Betancourt-Calle
authors.forename: R
authors.initials: R
authors.lastname: Mann-Blakeney
authors.forename: T
authors.initials: T
authors.lastname: Foushee
authors.forename: C M
authors.initials: CM
authors.lastname: Isales
authors.forename: W B
authors.initials: WB
authors.lastname: Bollag
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology*; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D002217:Carbachol / Q000494:pharmacology*; D002417:Cattle; D002478:Cells, Cultured; D004075:Diglycerides / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation / Q000187:drug effects; D019808:Losartan / Q000494:pharmacology; D010739:Phospholipase D / Q000378:metabolism*; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D011945:Receptors, Angiotensin / Q000502:physiology; D015384:Zona Glomerulosa / Q000201:enzymology*
chemical_list: D057911:Angiotensin Receptor Antagonists; D004075:Diglycerides; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D011945:Receptors, Angiotensin; D000804:Angiotensin II; D002217:Carbachol; D010739:Phospholipase D; D019808:Losartan